C P Selinger1, G C Parkes2, A Bassi3, E Fogden4, B Hayee5, J K Limdi6, H Ludlow7, S McLaughlin8, P Patel9, M Smith10, T Raine11. 1. Leeds Teaching Hospitals NHS Trust, Leeds, UK. 2. Royal London Hospital, Barts Heath, London, UK. 3. St Helens and Knowsley Teaching Hospitals NHS Trust, St Helens, UK. 4. Sandwell and West Birmingham Hospitals, Birmingham, UK. 5. King's College Hospital NHS Foundation Trust, London, UK. 6. Pennine Acute Hospitals NHS Trust, Manchester, UK. 7. Cardiff and Vale University Health Board, Cardiff, UK. 8. The Royal Bournemouth and Christchurch Hospitals NHS Trust, Bournemouth, UK. 9. Epsom and St Helier University Hospitals NHS, Epsom, UK. 10. Brighton and Sussex University Hospitals, Brighton, UK. 11. Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Abstract
BACKGROUND: Corticosteroids are central to inducing remission in inflammatory bowel disease (IBD) but are ineffective maintenance agents. AIM: To benchmark steroid usage in British outpatients and assess factors associated with excess exposure. METHODS: We recorded steroid use in unselected IBD outpatients. Cases meeting criteria for steroid dependency or excess were blind peer reviewed to determine whether steroid prescriptions were avoidable. Associations between steroid use and patient/institutional factors were analysed. RESULTS: Of 1176 patients, 30% received steroids in the prior 12 months. 14.9% had steroid dependency or excess, which was more common in moderate/severe ulcerative colitis (UC) than Crohn's disease (CD) (42.6% vs 28.1%; P = .027). Steroid dependency or excess was deemed avoidable in 49.1%. The annual incidence of inappropriate steroid excess was 7.1%. Mixed-effects logistic regression analysis revealed independent predictors of inappropriate steroid excess. The odds ratio (OR, 95%CI) for moderate/severe compared to mild/quiescent disease activity was 4.59 (1.53-20.64) for UC and 4.60 (2.21-12.00) for CD. In CD, lower rates of inappropriate steroid excess were found in centres with an IBD multi-disciplinary team (OR 0.62 [0.46-0.91]), whilst dedicated IBD clinics protected against inappropriate steroid excess in UC (OR 0.64, 95% CI 0.21-0.94). The total number of GI trainees was associated with rates of inappropriate steroid excess. CONCLUSIONS: Steroid dependency or excess occurred in 14.9% of British IBD patients (in 7.1% potentially avoidable). We demonstrated positive effects of service configurations (IBD multi-disciplinary team, dedicated IBD clinics). Routine recording of steroid dependency or excess is feasible and should be considered a quality metric.
BACKGROUND: Corticosteroids are central to inducing remission in inflammatory bowel disease (IBD) but are ineffective maintenance agents. AIM: To benchmark steroid usage in British outpatients and assess factors associated with excess exposure. METHODS: We recorded steroid use in unselected IBD outpatients. Cases meeting criteria for steroid dependency or excess were blind peer reviewed to determine whether steroid prescriptions were avoidable. Associations between steroid use and patient/institutional factors were analysed. RESULTS: Of 1176 patients, 30% received steroids in the prior 12 months. 14.9% had steroid dependency or excess, which was more common in moderate/severe ulcerative colitis (UC) than Crohn's disease (CD) (42.6% vs 28.1%; P = .027). Steroid dependency or excess was deemed avoidable in 49.1%. The annual incidence of inappropriate steroid excess was 7.1%. Mixed-effects logistic regression analysis revealed independent predictors of inappropriate steroid excess. The odds ratio (OR, 95%CI) for moderate/severe compared to mild/quiescent disease activity was 4.59 (1.53-20.64) for UC and 4.60 (2.21-12.00) for CD. In CD, lower rates of inappropriate steroid excess were found in centres with an IBD multi-disciplinary team (OR 0.62 [0.46-0.91]), whilst dedicated IBD clinics protected against inappropriate steroid excess in UC (OR 0.64, 95% CI 0.21-0.94). The total number of GI trainees was associated with rates of inappropriate steroid excess. CONCLUSIONS:Steroid dependency or excess occurred in 14.9% of British IBDpatients (in 7.1% potentially avoidable). We demonstrated positive effects of service configurations (IBD multi-disciplinary team, dedicated IBD clinics). Routine recording of steroid dependency or excess is feasible and should be considered a quality metric.
Authors: Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne Journal: Gut Date: 2019-09-27 Impact factor: 23.059
Authors: S Kurnool; N H Nguyen; J Proudfoot; P S Dulai; B S Boland; N Vande Casteele; E Evans; E L Grunvald; A Zarrinpar; W J Sandborn; S Singh Journal: Aliment Pharmacol Ther Date: 2018-04-17 Impact factor: 8.171
Authors: Jonathan Blackwell; Christian Selinger; Tim Raine; Gareth Parkes; Melissa A Smith; Richard Pollok Journal: Frontline Gastroenterol Date: 2020-04-02
Authors: Maryam Alkhatry; Ahmad Al-Rifai; Vito Annese; Filippos Georgopoulos; Ahmad N Jazzar; Ahmed M Khassouan; Zaher Koutoubi; Rahul Nathwani; Mazen S Taha; Jimmy K Limdi Journal: World J Gastroenterol Date: 2020-11-21 Impact factor: 5.742
Authors: Martin McDonnell; Richard J Harris; Florina Borca; Tilly Mills; Louise Downey; Suranga Dharmasiri; Mayank Patel; Benjamin Zare; Matt Stammers; Trevor R Smith; Richard Felwick; J R Fraser Cummings; Hang T T Phan; Markus Gwiggner Journal: BMJ Open Gastroenterol Date: 2020-11
Authors: Jonathan Blackwell; Christopher Alexakis; Sonia Saxena; Hanna Creese; Alex Bottle; Irene Petersen; Matthew Hotopf; Richard C G Pollok Journal: BMJ Open Gastroenterol Date: 2021-05
Authors: Marco Vincenzo Lenti; Sara Cococcia; Jihane Ghorayeb; Antonio Di Sabatino; Christian P Selinger Journal: Intern Emerg Med Date: 2019-12-31 Impact factor: 3.397